300
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

, &
Pages 467-473 | Received 07 Dec 2015, Accepted 10 Feb 2016, Published online: 29 Feb 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Kazuki Orime & Yasuo Terauchi. (2020) Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 21:17, pages 2101-2114.
Read now
María Molina-Vega, Araceli Muñoz-Garach, José C. Fernández-García & Francisco J. Tinahones. (2018) The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert Opinion on Drug Safety 17:8, pages 815-824.
Read now
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
André J. Scheen. (2017) Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 13:5, pages 583-592.
Read now

Articles from other publishers (5)

Wanhong Wu, Rongfang Lin, Meng Ke, Lingling Ye & Cuihong Lin. (2023) Physiologically Based Pharmacokinetic Modeling Characterizes the Drug‐Drug Interaction Between Saxagliptin and Rifampicin in Patients With Renal Impairment. The Journal of Clinical Pharmacology.
Crossref
Min Wu, Qian‐Qian Li, Hong Zhang, Xiao‐Xue Zhu, Xiao‐Jiao Li, Ying Li, Hai‐Gang Sun & Yan‐Hua Ding. (2021) Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase‐4 Inhibitor: A Randomized, Double‐Blinded, Placebo‐Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus. Clinical Pharmacology in Drug Development 10:6, pages 660-668.
Crossref
Maryam Rameshrad, Bibi Marjan Razavi, Gordon A. A. Ferns & Hossein Hosseinzadeh. (2019) Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning. DARU Journal of Pharmaceutical Sciences 27:1, pages 341-360.
Crossref
David W. Boulton. (2016) Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clinical Pharmacokinetics 56:1, pages 11-24.
Crossref
Yanwei Li, Lin Li & Christian Hölscher. (2016) Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Reviews in the Neurosciences 27:7, pages 689-711.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.